1. Home
  2. HRMY vs DV Comparison

HRMY vs DV Comparison

Compare HRMY & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$27.73

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo DoubleVerify Holdings Inc.

DV

DoubleVerify Holdings Inc.

HOLD

Current Price

$10.15

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
DV
Founded
2017
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
HRMY
DV
Price
$27.73
$10.15
Analyst Decision
Buy
Buy
Analyst Count
10
17
Target Price
$46.70
$16.18
AVG Volume (30 Days)
900.4K
3.1M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
0.30
Revenue
$868,453,000.00
$748,291,000.00
Revenue This Year
$19.87
$12.68
Revenue Next Year
$12.49
$9.75
P/E Ratio
$10.22
$33.40
Revenue Growth
21.51
13.92
52 Week Low
$25.52
$7.61
52 Week High
$40.87
$16.82

Technical Indicators

Market Signals
Indicator
HRMY
DV
Relative Strength Index (RSI) 32.88 50.29
Support Level $25.71 $10.18
Resistance Level $28.99 $11.60
Average True Range (ATR) 0.75 0.34
MACD 0.22 -0.03
Stochastic Oscillator 26.60 31.02

Price Performance

Historical Comparison
HRMY
DV

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About DV DoubleVerify Holdings Inc.

DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.

Share on Social Networks: